Literature DB >> 20654759

Effect of depot medroxyprogesterone acetate on postpartum depression.

Rita Tsai1, Jonathan Schaffir.   

Abstract

BACKGROUND: Depot medroxyprogesterone acetate (DMPA) is commonly prescribed to women immediately postpartum due to its efficacy, convenience and lack of estrogen. It is unclear whether administering a progestin injection can affect the course of postpartum depression (PPD), which some suspect to be influenced by hormonal changes. In this retrospective study, the objective was to determine whether DMPA administered immediately postpartum influences the development of PPD. STUDY
DESIGN: A retrospective review of a total of 404 charts was conducted of clinic patients who were scheduled for 6-week postpartum visits at a major medical center, where all patients are routinely asked to complete the Edinburgh Postnatal Depression Scale (EPDS). The average scores on the EPDS at these visits were compared between patients who had received DMPA prior to postpartum discharge from the hospital and patients who had not received any hormonal contraception by using an unpaired t test. In addition, the proportions of women diagnosed with PPD via the scale were compared via contingency tables.
RESULTS: Fifty-five women who had received immediate DMPA were compared with 192 women with no hormonal contraception after delivery. The groups were similar in parity, race, mode of delivery and weight, but women receiving DMPA were significantly younger (24.2 vs. 26.2 years, p=.03). Mean EPDS scores at 6 weeks postpartum were not statistically significant between the groups (5.02 vs. 6.17, p=.16). Six patients (10.9%) who received immediate DMPA were diagnosed with PPD based on EPDS scores greater than or equal to 13, while 27 (14.1%) in the comparison group had PPD (p=.88).
CONCLUSION: Administration of DMPA in the immediate postpartum period does not appear to predispose women to PPD. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20654759     DOI: 10.1016/j.contraception.2010.03.004

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  7 in total

1.  Postpartum hormonal contraception use and incidence of postpartum depression: a systematic review.

Authors:  Angeline Ti; Kathryn M Curtis
Journal:  Eur J Contracept Reprod Health Care       Date:  2019-03-28       Impact factor: 1.848

2.  Hormonal Contraception and Risk of Psychiatric and Other Noncommunicable Diseases in HIV-Infected Women.

Authors:  Jessica L Castilho; Cathy A Jenkins; Bryan E Shepherd; Sally S Bebawy; Megan Turner; Timothy R Sterling; Vlada V Melekhin
Journal:  J Womens Health (Larchmt)       Date:  2015-03-09       Impact factor: 2.681

Review 3.  Progesterone, reproduction, and psychiatric illness.

Authors:  Lindsay R Standeven; Katherine O McEvoy; Lauren M Osborne
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-06-18       Impact factor: 5.237

Review 4.  Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.

Authors:  Ariela Frieder; Madeleine Fersh; Rachel Hainline; Kristina M Deligiannidis
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

Review 5.  Pharmacotherapy of postpartum depression: an update.

Authors:  Deborah R Kim; C Neill Epperson; Amy R Weiss; Katherine L Wisner
Journal:  Expert Opin Pharmacother       Date:  2014-04-29       Impact factor: 3.889

6.  Hormonally Active Contraceptives Part I: Risks Acknowledged and Unacknowledged.

Authors:  William V Williams; Joel Brind; Laura Haynes; Michael D Manhart; Hanna Klaus; Angela Lanfranchi; Gerard Migeon; Mike Gaskins; Elvis I Seman; Lester Ruppersberger; Kathleen M Raviele
Journal:  Linacre Q       Date:  2021-01-27

Review 7.  Prenatal contraceptive counseling and method provision after childbirth.

Authors:  Anita L Nelson
Journal:  Open Access J Contracept       Date:  2015-05-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.